Kamada Selected as a Winner of the Genesis Prize Foundation and Start-Up Nation Central Competition
January 05, 2021 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it has been selected as one of 10 winners of...
Kamada Added to the NASDAQ Biotechnology Index
December 21, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced that it has been selected for addition to...
Kamada Reports Third Quarter and First Nine Months of 2020 Financial Results, Recent Achievements and Corporate Development
November 11, 2020 07:00 ET
|
Kamada Ltd.
Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue...
Kamada to Announce Third Quarter Ended September 30, 2020 Financial Results and Host Conference Call on November 11, 2020
November 04, 2020 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kamada Announces Supply Agreement with Israeli Ministry of Health for its Investigational IgG Product for COVID-19; Initial Order Expected to Generate $3.4 Million in Revenue in First Quarter of 2021
October 19, 2020 07:00 ET
|
Kamada Ltd.
Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of HealthInitial Order Sufficient to Treat 500 Patients Positive Interim Safety and Symptoms Improvement...
Kamada Provides Update on 2021 GLASSIA® Supply to Takeda
October 07, 2020 06:30 ET
|
Kamada Ltd.
Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply AgreementKamada Projects...
Kamada Announces Completion of Enrollment and Initial Interim Results from its Phase 1/2 Clinical Trial in Israel of its Plasma-Derived Hyperimmune Immunoglobulin (IgG) Product as a Potential Treatment for Coronavirus Disease (COVID-19)
September 08, 2020 07:00 ET
|
Kamada Ltd.
The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyperimmune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with PneumoniaSymptoms Improvement...
Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective
August 19, 2020 07:00 ET
|
Kamada Ltd.
The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.The Study Met its Primary Objective, Which Was to...
Kamada Announces Changes to its Board of Directors
August 12, 2020 07:30 ET
|
Kamada Ltd.
Lilach Asher Topilsky, a Director on the Company’s Board and a Senior Partner at FIMI Opportunity Funds, Appointed Chairman Current Chairman, Leon Recanati, Remains on the Board as a Director Ari...
Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position
August 12, 2020 07:00 ET
|
Kamada Ltd.
Second Quarter Revenues were $33.1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019 Net Income for the Second Quarter and for the First Half of...